35 results
PRE 14A
SHPH
Shuttle Pharmaceuticals Holdings Inc
10 Jun 24
Preliminary proxy
6:12am
an invaluable asset to Shuttle Pharma’s mission as the Company advances its pharmaceutical candidates in clinical trials. He has held positions of Senior
8-K
EX-99.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 May 24
Regulation FD Disclosure
4:15pm
pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer
8-K
EX-99.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
14 May 24
Shuttle Pharma Provides First Quarter 2024 Corporate Update
9:00am
and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission
8-K
EX-99.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Apr 24
Other Events
4:36pm
pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (“RT”). Our mission is to improve the lives of cancer
8-K
EX-99.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 Mar 24
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
9:00am
specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve
424B3
jjb eoak7wpjqxsy
22 Mar 24
Prospectus supplement
6:07am
8-K
EX-99.1
zei2flrk rrt
5 Mar 24
Shuttle Pharmaceuticals to Present at About Shuttle Pharmaceuticals
9:00am
8-K
EX-99.1
ntboukwz43v j29h
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
8-K
EX-99.1
pmgw9xwcn6kbvu8
8 Jan 24
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
9:05am
8-K
EX-99.1
op2kf8 q26wdm
11 Dec 23
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
8-K
EX-99.1
62u6k5a2geo
30 Nov 23
Other Events
9:00am
8-K
EX-99.1
yuc3 9lj1oelqip
14 Nov 23
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
12:00am
8-K
EX-99.1
k5ksyfay5cb
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm
8-K
EX-99.1
yfd5c29g
10 Oct 23
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
9:00am
8-K
EX-99.1
sarit7jypx7
25 Sep 23
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
424B3
ucc38dm4
24 Aug 23
Prospectus supplement
2:00pm
8-K
EX-99.1
u491eodtxfq857j2vn
15 Aug 23
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
9:00am
8-K
EX-99.1
06nbn vyvb9g55254220
3 Aug 23
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
9:00am